Melanoma Clinical Trial
Study in Subjects With Small Primary Choroidal Melanoma
Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Full Description
This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma.
Throughout the study, subjects will be monitored through medical and ophthalmic assessments. Subjects will be followed for a total of 2 years.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of choroidal melanoma
Exclusion Criteria:
Have known contraindications or sensitivities to the study drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Tucson Arizona, 85710, United States
Los Angeles California, 90095, United States
Palo Alto California, 94303, United States
Sacramento California, 95819, United States
Denver Colorado, 80210, United States
Boston Massachusetts, 02114, United States
Ann Arbor Michigan, 48105, United States
Royal Oak Michigan, 48073, United States
Minneapolis Minnesota, 55404, United States
New York New York, 10027, United States
Philadelphia Pennsylvania, 19107, United States
Greenville South Carolina, 29605, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.